Global News Hubb
Advertisement Banner
  • Home
  • Politics
  • Finance
  • Technology
  • Contact
No Result
View All Result
  • Home
  • Politics
  • Finance
  • Technology
  • Contact
No Result
View All Result
Wellnessnewshubb
No Result
View All Result
Home Politics

STAT+: U.S. Supreme Court gives Amgen a boost by agreeing to review a closely watched patent case

admin by admin
November 6, 2022
in Politics



In a boost for Amgen, the U.S. Supreme Court agreed to hear a case in which the company argued a federal appeals court incorrectly determined its patent claims on a cholesterol medication are invalid.

At issue is a long-running battle between Amgen and a pair of rivals — Sanofi and Regeneron Pharmaceuticals — over the market for injectable cholesterol treatments. Amgen filed a lawsuit against the other companies in 2014 for allegedly infringing patents when they sought regulatory approval for their own medication. Both drugs won U.S. regulatory approval the subsequent year.

Continue to STAT+ to read the full story…



Source link

Previous Post

Axis Bank increases interest rates on FDs by up to 115 basis points

Next Post

Past eight years warmest on record, UN report warns | Climate News

Next Post

Past eight years warmest on record, UN report warns | Climate News

Recommended

Basis Technologies Enables Cookieless Conversion Attribution

3 months ago

Ghanaian startup FLUID launches platform helping smallholder farmers access credit

1 day ago

© 2022 Global News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • Politics
  • Finance
  • Technology
  • Contact

Newsletter Sign Up.

No Result
View All Result
  • Home
  • Politics
  • Finance
  • Technology
  • Contact

© 2022 Global News Hubb All rights reserved.